News for BeiGene Ltd (spons. ADRs)

InvestorPlace 1,178d

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs

InvestorPlace 1,181d

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.

Benzinga 1,189d

Analyst Ratings For BeiGene

Benzinga 1,189d

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2022

Benzinga 1,189d

10 Biggest Price Target Changes For Thursday

Seeking Alpha 1,190d

Zai Lab, 111 top healthcare gainers; Talis Biomedical, Incannex lead losers' pack

Seeking Alpha 1,191d

BeiGene wins approval for Brukinsa in Israel for another form of lymphoma

Benzinga 1,193d

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

Benzinga 1,195d

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today

InvestorPlace 1,195d

Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?

Benzinga 1,195d

The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China

Seeking Alpha 1,195d

Hong Kong market drops after SEC hints at delisting some Chinese stocks

Seeking Alpha 1,195d

BeiGene's tislelizumab gets approval in China for expanded use in solid tumors

Benzinga 1,196d

Chinese Stocks Are Falling: What's Going On?

Seeking Alpha 1,196d

Chinese techs in broad slump as SEC hints at delisting actions

Seeking Alpha 1,196d

Zai Lab, Beigene down amid potential violation of foreign government ownership law

Benzinga 1,203d

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO

Seeking Alpha 1,203d

BeiGene Brukinsa gets approval in Canada for blood cancer subtype

Seeking Alpha 1,209d

BeiGene GAAP EPADS of -$6.16 misses by $1.29, revenue of $214M beats by $0.64M

Seeking Alpha 1,212d

BeiGene's Brukinsa gets FDA review for expanded use in blood cancer subtype

Seeking Alpha 1,217d

BeiGene's Brukinsa for blood cancer subtype gets approval in Switzerland

Benzinga 1,220d

CStone's Commercialization Capacity Put to Test With Latest Drug Approval

Seeking Alpha 1,225d

Drugs developed with China-based trials could face additional FDA scrutiny - WSJ

Seeking Alpha 1,233d

Will Novartis Q4 results bring positive surprise amid buzz surrounding Sandoz?

Benzinga 1,237d

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

Seeking Alpha 1,237d

BeiGene's Brukinsa application accepted in China for chronic lymphocytic leukemia

Benzinga 1,239d

New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report

Seeking Alpha 1,241d

BeiGene reports positive findings from Phase 3 trial of tislelizumab + chemotherapy in gastric cancer

Benzinga 1,245d

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug

Seeking Alpha 1,245d

BeiGene receives approval of supplemental new drug application for BRUKINSA in China

Benzinga 1,246d

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

Seeking Alpha 1,259d

BeiGene's tislelizumab OK'd in China as second or third-line treatment for lung cancer

InvestorPlace 1,274d

BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today

Seeking Alpha 1,276d

BeiGene broadens partnership with Novartis for TIGIT inhibitor ociperlimab

Seeking Alpha 1,280d

AGEN, LYG and ARVL among pre market gainers

Benzinga 1,280d

46 Biggest Movers From Yesterday

Seeking Alpha 1,281d

Zai Lab defended at JPMorgan amid clampdown on Chinese firms

Benzinga 1,281d

36 Stocks Moving In Wednesday's Mid-Day Session

Benzinga 1,281d

20 Stocks Moving in Wednesday's Pre-Market Session

InvestorPlace 1,281d

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Seeking Alpha 1,281d

BeiGene shares falls 7% on Shanghai debut

Seeking Alpha 1,281d

BeiGene's Brukinsa authorized in U.K. for Waldenström’s macroglobulinemia

Benzinga 1,286d

The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares

Seeking Alpha 1,286d

BeiGene reports tislelizumab data in Phase 3 nasopharyngeal cancer study

PR Newswire 1,287d

Direxion Launches mRNA ETF (MSGR)

Seeking Alpha 1,287d

First patient dosed in pivotal trial for Zymeworks/BeiGene gastroesophageal cancer trial

Benzinga 1,287d

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO

Benzinga 1,290d

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More

Benzinga 1,293d

The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering

Seeking Alpha 1,293d

BeiGene's Sylvant OK'd in China for idiopathic multicentric castleman disease

	
		OSZAR »